Aldeyra Therapeutics’ (ALDX) Neutral Rating Reaffirmed at HC Wainwright

Aldeyra Therapeutics (NASDAQ:ALDX)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $2.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 53.26% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday. Finally, Weiss Ratings downgraded shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, September 14th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Aldeyra Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Trading Down 1.1%

Aldeyra Therapeutics stock traded down $0.02 during mid-day trading on Wednesday, hitting $1.31. The stock had a trading volume of 743,120 shares, compared to its average volume of 1,753,246. The firm has a market capitalization of $78.73 million, a P/E ratio of -3.35 and a beta of 1.20. The firm’s 50 day moving average is $1.48 and its 200 day moving average is $1.73. Aldeyra Therapeutics has a one year low of $1.07 and a one year high of $5.93.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). As a group, equities research analysts forecast that Aldeyra Therapeutics will post -0.39 earnings per share for the current year.

Institutional Trading of Aldeyra Therapeutics

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $2,678,000. 683 Capital Management LLC increased its position in shares of Aldeyra Therapeutics by 86.6% during the 4th quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after purchasing an additional 710,000 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Aldeyra Therapeutics by 146.6% during the 1st quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock valued at $1,459,000 after purchasing an additional 513,187 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $1,007,000. Finally, 1492 Capital Management LLC bought a new position in shares of Aldeyra Therapeutics during the 4th quarter valued at approximately $1,157,000. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics News Summary

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: Aldeyra announced its intent to submit a formal dispute resolution request (FDRR) regarding the FDA’s third complete response letter for reproxalap. The move could provide another opportunity to address the agency’s concerns and seek reconsideration of the dry-eye treatment. Aldeyra Announces Intent to Submit Formal Dispute Resolution Request
• Positive Sentiment: Investors initially responded favorably to the dispute-resolution strategy, with reports describing a rally in ALDX shares as the company pushed back against the FDA decision. Aldeyra Fights Back Against FDA Rejection
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating, indicating that the analyst sees meaningful upside if Aldeyra can advance reproxalap through the regulatory process.
• Neutral Sentiment: HC Wainwright maintained a “neutral” rating but set a $2.00 price target, implying substantial upside from recently quoted levels while signaling that significant regulatory and execution risks remain.
• Negative Sentiment: The FDRR follows a third FDA complete response letter, underscoring repeated regulatory setbacks. The dispute process does not guarantee approval and may prolong development costs and timelines for the company.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research centers on reactive aldehyde species, or RASP, which are inflammatory mediators that can contribute to tissue damage and disease progression.

Aldeyra’s lead investigational product is reproxalap, a small-molecule RASP inhibitor being developed for ocular conditions, including dry eye disease and allergic conjunctivitis. The company has also developed ADX-2191, an investigational intravitreal formulation of methotrexate intended for the treatment of certain rare retinal diseases, including proliferative vitreoretinopathy and retinitis pigmentosa.

Founded in 2008 and headquartered in Lexington, Massachusetts, Aldeyra conducts its research and clinical development activities primarily in the United States.